Revvity Broadens Relationship with Genomics England to Advance Genomics in the UK
Revvity to Present at 7th Annual Evercore ISI HealthCONx Conference
Scale Biosciences and Revvity’s BioLegend Launch First-of-its-Kind Solution for High Parameter Protein Profiling of Single Cells
Revvity to Host Investor Day and Updates Organizational Structure to Reflect Recent Transformation
Revvity, Inc. (NYSE: RVTY) had its price target raised by analysts at TD Cowen from $141.00 to $144.00. They now have a "buy" rating on the stock.